| Trial ID: | L3047 |
| Source ID: | NCT00289848
|
| Associated Drug: |
Sitagliptin Phosphate
|
| Title: |
MK0431 Monotherapy Study in Patients With Type 2 Diabetes Mellitus (0431-040)
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT00289848/results
|
| Conditions: |
Type 2 Diabetes Mellitus
|
| Interventions: |
DRUG: sitagliptin phosphate|DRUG: Comparator: placebo
|
| Outcome Measures: |
Primary: Change From Baseline in Hemoglobin A1c (HbA1c) at Week 18, A1C was measured as a percent. Thus, this change from baseline reflects the Week 18 A1C percent minus the Week 0 A1C percent., Baseline and Week 18 | Secondary: Change From Baseline in Fasting Plasma Glucose (FPG) at Week 18, Change from baseline at Week 18 is defined as Week 18 FPG minus Week 0 FPG., Baseline and Week 18|Change From Baseline in 2-hr Post-Meal Glucose (PMG) at Week 18, Change from baseline at Week 18 is defined as Week 18 minus Week 0., Baseline and Week 18
|
| Sponsor/Collaborators: |
Sponsor: Merck Sharp & Dohme LLC
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE3
|
| Enrollment: |
530
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2006-03
|
| Completion Date: |
2007-03
|
| Results First Posted: |
2010-04-02
|
| Last Update Posted: |
2015-06-15
|
| Locations: |
|
| URL: |
https://clinicaltrials.gov/show/NCT00289848
|
